1. Home
  2. PSN vs GRFS Comparison

PSN vs GRFS Comparison

Compare PSN & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Parsons Corporation

PSN

Parsons Corporation

HOLD

Current Price

$55.95

Market Cap

6.0B

Sector

Technology

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$8.52

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSN
GRFS
Founded
1944
1940
Country
United States
Spain
Employees
N/A
25247
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
5.5B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
PSN
GRFS
Price
$55.95
$8.52
Analyst Decision
Strong Buy
Hold
Analyst Count
13
2
Target Price
$79.50
$10.15
AVG Volume (30 Days)
1.2M
680.4K
Earning Date
04-29-2026
07-28-2022
Dividend Yield
N/A
1.70%
EPS Growth
3.77
N/A
EPS
2.20
N/A
Revenue
$6,364,245,000.00
N/A
Revenue This Year
$5.76
$4.69
Revenue Next Year
$7.59
$6.49
P/E Ratio
$25.48
$18.67
Revenue Growth
N/A
N/A
52 Week Low
$49.38
$6.86
52 Week High
$89.50
$11.14

Technical Indicators

Market Signals
Indicator
PSN
GRFS
Relative Strength Index (RSI) 47.75 57.29
Support Level $49.38 $8.25
Resistance Level $67.46 $9.08
Average True Range (ATR) 1.88 0.22
MACD 0.74 0.11
Stochastic Oscillator 67.42 90.12

Price Performance

Historical Comparison
PSN
GRFS

About PSN Parsons Corporation

Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe. The company derives maximum revenue from Federal Solutions segment. Geographically, the company derives revenue from North America; Middle East; and Rest of the World, of which North America derives maximum revenue.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: